Exelixis Balance Sheet Health

Financial Health criteria checks 6/6

Exelixis has a total shareholder equity of $2.1B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $2.8B and $653.4M respectively. Exelixis's EBIT is $402.9M making its interest coverage ratio -4.9. It has cash and short-term investments of $1.0B.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ratio-4.9x
CashUS$1.00b
EquityUS$2.12b
Total liabilitiesUS$653.39m
Total assetsUS$2.77b

Recent financial health updates

No updates

Recent updates

Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Sep 02
Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Exelixis Comes Up Aces

Aug 08

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Jun 14
If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24
It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07
Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26
We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27
Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30
An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise

Oct 18

Financial Position Analysis

Short Term Liabilities: EXEL's short term assets ($1.5B) exceed its short term liabilities ($345.7M).

Long Term Liabilities: EXEL's short term assets ($1.5B) exceed its long term liabilities ($307.7M).


Debt to Equity History and Analysis

Debt Level: EXEL is debt free.

Reducing Debt: EXEL had no debt 5 years ago.

Debt Coverage: EXEL has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: EXEL has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies